
Antiangiogenic Gene Therapy, Added to Standard Treatment, Boosts Survival in Recurrent Glioblastoma
Avastin plus a novel antiangiogenic gene therapy resulted in significantly better overall survival for patients with recurrent glioblastoma multiforme.




























